Suarez-Carmona Meggy, Halama Niels
Department of Cancer Immunology & Cancer Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany; Helmholtz Institute for Translational Oncology (HI-TRON), Mainz, Germany.
Department of Cancer Immunology & Cancer Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany; Helmholtz Institute for Translational Oncology (HI-TRON), Mainz, Germany; University Cancer Center Mainz (UCT Mainz), University Medical Center of the Johannes Gutenberg-University of Mainz, Mainz, Germany; Department of Hematology, Medical Oncology and Pneumology, University Medical Center of the Johannes Gutenberg-University of Mainz, Mainz, Germany.
Trends Cancer. 2024 Dec;10(12):1093-1094. doi: 10.1016/j.trecan.2024.10.006. Epub 2024 Oct 24.
Neoadjuvant immune checkpoint inhibition (ICI) is a new approach to treat patients with colorectal cancer (CRC). The effects of combined neoadjuvant ICI in locally advanced, DNA mismatch repair (dMMR)-deficient/microsatellite instable (MSI) CRC were recently reported by de Gooyer et al. from the NICHE-3 trial. Further studies will determine whether these impressive pathological responses lead to long-term clinical benefit.
新辅助免疫检查点抑制（ICI）是治疗结直肠癌（CRC）患者的一种新方法。de Gooyer等人在NICHE - 3试验中最近报告了新辅助ICI联合治疗局部晚期、DNA错配修复（dMMR）缺陷/微卫星不稳定（MSI）CRC的效果。进一步的研究将确定这些令人印象深刻的病理反应是否会带来长期的临床益处。
